Predict your next investment

Corporation
bionorpharma.com

See what CB Insights has to offer

Partners & Customers

1

About Bionor Pharma

Bionor Pharma (OSE: BIONOR) is a biopharmaceutical company that is developing vaccines targeted at rapidly mutating virus infections such as HIV, Hepatitis C, and Influenza.

Bionor Pharma Headquarter Location

Kronprinsesse Maerthas plass 1

Oslo, NO-0116,

Norway

+47 23 01 09 60

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Bionor Pharma News

Solon Eiendom ASA : Sale of non-core assets and Bionor Pharma update

May 23, 2017

Solon Eiendom ASA : Sale of non-core assets and Bionor Pharma update May 23, 2017 08:51 ET | Source: Solon Eiendom ASA SEA20170523_Press_release_May_2017_sale_of_non_core_assets.pdf Oslo, May 23, 2017 - As previously communicated, Solon has been in dialogue regarding the sale of non-core assets. Solon has now entered into binding agreements for the sale of three real estate properties including two commercial properties. The combined gain on sale is approximately NOK 19 million and will result in increased liquidity of approximately NOK 76 million. These sales will be recognized in Q2 and Q3 this year. Solon has, after the above mentioned sales, divested all non core real estate assets. As previously communicated, the biopharmaceutical division engaged a team of international industry experts to propose an updated development plan and strategic partnership assessment. The team has been in dialogue with several potential partners and the response has been positive. However, it has not yet been possible to conclude a strategic partnership on acceptable terms. As the current agreement with the team of industry experts expires at the end of May, various alternatives are being considered by management including engaging advisors to explore market opportunities or winding down the activities. Until a decision is reached, the current activities aimed at maintaining the value of the related intellectual property rights will continue while at the same time reducing the current cost base to a minimal level. The planned cost reducing actions will decrease the annual cash burn for the biopharmaceutical division from approximately NOK 24 million to NOK 14 million with full effect anticipated from end of Q3 2017. For further information, please contact: Andreas Martinussen, Chief Executive Officer, Solon Eiendom ASA Tel:     +47 400 00 405, email:    am@soloneiendom.no Scott Danielsen, Chief Financial Officer, Solon Eiendom ASA Tel:     +47 952 55 620, email:  sd@soloneiendom.no About Solon Eiendom Solon Eiendom is a Norwegian residential real estate development company focusing on the Oslo and Akershus region. Solon Eiendom was established in 2006 by founder Simen Thorsen and investor Tore Aksel Voldberg. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachments:

Bionor Pharma Acquisitions

1 Acquisition

Bionor Pharma acquired 1 company. Their latest acquisition was Solon Eiendom on November 22, 2016.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

11/22/2016

$991

Acquired

4

Date

11/22/2016

Investment Stage

Companies

Valuation

$991

Total Funding

Note

Acquired

Sources

4

Bionor Pharma Partners & Customers

1 Partners and customers

Bionor Pharma has 1 strategic partners and customers. Bionor Pharma recently partnered with Celgene on August 8, 2015.

Date

Type

Business Partner

Country

News Snippet

Sources

8/4/2015

Licensor

Celgene

United States

Bionor Pharma ASA : enters into romidepsin supply agreement enabling advancement of its HIV therapeutic vaccine with Vacc-4x into full scale clinical Phase II

Bionor enters into romidepsin supply agreement enabling advancement of its HIV therapeutic vaccine with Vacc-4x into full scale clinical Phase II

1

Date

8/4/2015

Type

Licensor

Business Partner

Celgene

Country

United States

News Snippet

Bionor Pharma ASA : enters into romidepsin supply agreement enabling advancement of its HIV therapeutic vaccine with Vacc-4x into full scale clinical Phase II

Bionor enters into romidepsin supply agreement enabling advancement of its HIV therapeutic vaccine with Vacc-4x into full scale clinical Phase II

Sources

1

Bionor Pharma Team

2 Team Members

Bionor Pharma has 2 team members, including former Chief Executive Officer, Henrik Lund.

Name

Work History

Title

Status

Henrik Lund

Chief Executive Officer

Former

Vidar Wendel-Hansen

Executive Vice President

Former

Name

Henrik Lund

Vidar Wendel-Hansen

Work History

Title

Chief Executive Officer

Executive Vice President

Status

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.